Physicians' Academy for Cardiovascular Education

Real world data confirm CV benefits of SGLT-2 inhibitors in diabetic patients

Lower Rates of Hospitalization for Heart Failure and All-Cause Death in New Users of SGLT-2 Inhibitors: The CVD-REAL Study

Presented at ACC.17 by Mikhail Kosiborod

News - Mar. 19, 2017

Main results


In a large real-world study across six countries and a broad population of T2DM patients, treatment with SGLT-2i versus oGLDs was associated with significant reductions in hospitalisation for HF, all-cause death, and the combined endpoint of HF hospitalization or all-cause death. The observed CV benefits seem to be class-related and, given the broad population of patients with T2DM in general practice, may extrapolate to real world clinical practice. Since the majority (87%) of patients did not have known CV disease, these benefits may extend to those at the lower end of the risk spectrum.

No significant heterogeneity was observed between countries, despite geographic variations in use of SGLT-2i (predominance of canagliflozin in US and dapagliflozin in other countries).


Our coverage of ACC.17 is based on the information provided during the congress.

Share this page with your colleagues and friends: